info@biomedres.us   +1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Mini ReviewOpen Access

MRI and Pregnancy

Volume 3 - Issue 3

Pasquini L1* and Di Stasio M2

  • Author Information Open or Close
    • 1Neuroradiology Unit, NESMOS Department, La Sapienza University, Rome
    • 2Radiology Units, Department of Experimental and Clinical Biomedical Sciences, University of Florence - AOU Florence

    *Corresponding author: Pasquini L, Neuro radiology Unit, Sant’Andrea Hospital, Via di Grottarossa 1035, 00189, Rome

Received: March 18, 2018;   Published: March 29, 2018

DOI: 10.26717/BJSTR.2018.03.000897

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Magnetic Resonance Imaging (MRI) is indicated during pregnancy for both foetal pathology (CNS abnormalities, neck and oropharynx masses, diaphragmatic hernia, placental pathology, abdominal masses or intestinal pathology without sufficient characterization at ultrasound, suspected foetal infection) and maternal pathology (acute abdomen, appendicitis) [1,2]. The developing human foetus is considered particularly vulnerable to external insults, so that the possible consequences of MRI during pregnancy have been widely investigated to isolate possible side effects and identify the best safety parameters. The anatomy of the human foetus changes every week of gestation, affecting the interactions with the external environment. The development of the internal organs which are deputed to distribute and excrete chemicals (e.g.) strongly affects the pharmacokinetics of contrast agents. The main foetal risks during MR examinations include GBCArelated effects (nephrogenic system fibrosis - NSF -, teratogenicity, brain deposit) and physical effects (body temperature increase, acoustic injuries related to the scanner noise).

Abbreviations: MRI: Magnetic Resonance Imaging; GBCAs: Gadolinium-Based Contrast Agents; FAD: Food and Drug Administration; EMA: European Medicines Agency

Introduction| Conclusion| References|